banda transcan 2 2016ul

Title:
Establishing an algorithm for the early diagnosis and follow-up of patients with pancreatic neuroendocrine tumors

Project Coordinator:
Yvonne Kohl (Germany), Fraunhofer Institute for Biomedical Engineering IBMT, Medical Biotechnology, Sulzbach

Project Partners:
Alfredo Carrato (Spain), Ramon y Cajal University Hospital, Department of Medical Oncology, Madrid
Bozena Smolkova (Slovakia), Biomedical Research Center, Slovak Academy of Sciences, Cancer Research Institute, Department of Molecular Oncology, Bratislava
Vita Rovite (Latvia), Latvian Biomedical Research and Study Centre, Human Genetics and Molecular Medicine, Riga
Manousos Konstadoulakis (Greece), National and Kapodistrian University of Athens, 1st Department of Propaedeutic Surgery, Athens
David Hevia (Spain), Bioquochem Company, Department of Research and Development, Llanera, Asturias

Project Abstract:
Background and rationale: Standardized clinical management of pancreatic neuroendocrine tumours (PNETs) is restricted by different aspects of the disease, as its relative rarity, heterogeneous presentation, the limited understanding of tumour biology and the lack of risk stratification systems. While surgical excision remains the primary therapy, most patients are not candidates for resection.
Hypothesis: Prompt, specific and sensitive detection and characterisation of PNETs could lead to early detection, increasing the chance for surgical intervention and improve patients’ survival. Circulating tumour cells (CTCs) are considered attractive biomarkers for liquid biopsy as they represent an early step in blood-borne metastasis.
Aims: By building up a tissue bank of genetically characterized tumours, development of patient-derived xenografts (PDXs) and organoids, we aim to identify PNET-specific biomarkers urgently needed to design a NExT generation nanotechnology based microfluidic device and integrate the technology of minimally invasive liquid biopsy in the early detection of PNETs.
Methods: Serum and tissue samples will be collected from PNET patients and their clinical and lab records will be recorded. In clinical samples an expression study and genomic analysis will be performed by different molecular techniques whereas, in parallel organdies, PDX and CTC-derived xenografts (CDX) will be established. Based on the acquired data a NExT generation microfluidic device will be developed for PNET-detection and follow-up.
Expected results and potential impact: Better understanding of the etiopathogenetic determinants involved in PNETs formation resulting from the multidisciplinary collaboration within ‘NExT” consortium will hopefully deliver a nanotechnology-based microfluidic (next generation) device that by means of CTCs detection will present a powerful tool for the early detection of PNET tumors and patients follow-up, contributing to better medical treatment.

 

(Project funded under JTC 2017)


TRANSCAN News

 TRANSCAN-3 news on:
twitter logoinkedin social media logo

TRANSCAN-3   JOINT TRANSNATIONAL CALL 2022 on:
 "Novel translational approaches to tackle the challenges of hard-to-treat cancers from early diagnosis to therapy"  

is open for submission

Please visit the TRANSCAN-3 website at
https://transcan.eu/funding/calls/joint-call-jtc-2022-.kl


Other news:

The Digital Institute for Cancer Outcomes Research (DIGICORE),  is delighted to announce an innovative new training programme for early career researchers in oncology: IDEAL4RWE.
 Please register for an introductory webinar on the19th April 2022(https://lnkd.in/ez7y4kWU).
Brochure for more details: https://tinyurl.com/y7aurdtk


 The first TRANSCAN-3 call (JTC 2021) on:
"Next generation cancer immunotherapy: targeting the tumour microenvironment"
is closed for submission

International Networking Event (virtual)
on 22 April 2021 hrs 9:00 CET
will focus on the forthcoming co-funded JTC 2021 on:
"Next generation cancer immunotherapy: targeting the tumour microenvironment" 
the event is organized by TUBITAK under the “Turkey in Horizon 2020 Phase II” Technical Assistance Project
in cooperation with TRANSCAN-3

The new ERA-NET Cofund TRANSCAN-3:
 Sustained collaboration of national and regional programmes in cancer research
is funded by the European Commission under H2020  which started on 1st March 2021 and will last five years (G. A. no. 964264)

A TRANSCAN-2 brochure, highlighting key achievements, is available for download

 

Newsletters

The TRANSCAN-3 newsletters are published at: https://www.transcan.eu/

SUBSCRIBE to the newsletters
You can unsubscribe at any moment by clicking on the subscription preferences link at the bottom of a received newsletter


All the TRANSCAN-2 newsletters:

Newsletter 10, Sept.2020
Newsletter 9, Dec.2019

Newsletter 8, May 2019
Newsletter 7, Oct.2018
Newsletter 6, June 2108
Newsletter 5, March 2018
Newsletter 4, Dec. 2017
Newsletter 3, Sept. 2017
Newsletter 2, April 2017
Newsletter 1, Dec. 2016

eu flagship

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 643638.

Who's Online

We have 7 guests and no members online